Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b multicenter double-blind placebo-controlled study of obefazimod in moderately to severely active Crohn's disease
MOH_2026-05-24_016848Phase 3Not yet recruiting
- Sponsor
- Abivax
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of obefazimod in Crohn's disease (4 arms), sponsored by Abivax. Primary endpoint: Primary endpoint not specified. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
obefazimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2026-05-24_016848.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-05-24_016848.